GlaxoSmithKline (GSK), on of the world’s leading research-based pharmaceutical and healthcare companies, has completed the divestment of its thrombosis brands, Arixtra and Fraxiparine to the Aspen Group (Aspen) for £700 million, following regulatory approval of the transaction. The majority of commercial operations formally transferred to Aspen on January 1, 2014 with the remainder, along with the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.

GSK is committed to improving the quality of human life by enabling people to do more, feel better and live longer

Aspen is a global supplier of branded and generic pharmaceutical products as well as consumer and nutritional products in selected territories.